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fibers. These mice develop motor axonopathy and sensory 
deficits similar to those seen in DNP. Motor axon degenera-
tion was also observed in mice in which the IGF1 receptor 
(IGF1R) was conditionally depleted in motoneurons, indicat-
ing that reduced activity of IGF1 on IGF1R in motoneurons 
is responsible for the observed effect. These data provide evi-
dence that elevated expression of IGFBP5 in diabetic nerves 
reduces the availability of IGF1 for IGF1R on motor axons, 
thus leading to progressive neurodegeneration. Inhibition of 
IGFBP5 could thus offer novel treatment strategies for DNP.
Keywords Motor nerve biopsy · Diabetic 
polyneuropathy · Neuropathy · Neurotrophic factors · 
Axonal degeneration
Abstract Diabetic neuropathy (DNP), afflicting sensory 
and motor nerve fibers, is a major complication in diabetes. 
The underlying cellular mechanisms of axon degeneration 
are poorly understood. IGFBP5, an inhibitory binding pro-
tein for insulin-like growth factor 1 (IGF1) is highly up-regu-
lated in nerve biopsies of patients with DNP. We investigated 
the pathogenic relevance of this finding in transgenic mice 
overexpressing IGFBP5 in motor axons and sensory nerve 
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Introduction
Diabetic neuropathy (DNP) is a heterogeneous disorder, 
with sensory, motor, and autonomic system involvement 
[5], including small fiber disease, all leading to progressive 
disability [37, 40]. The etiopathogenesis of DNP is complex 
and involves metabolic, vascular, and immune-mediated 
components [50], but whether trophic factor dysregulation 
plays a role is still unclear. In a large study comparing dis-
ability in the elderly, motor performance was more reduced 
in diabetic than non-diabetic individuals and found to make 
a major contribution to overall disability [45]. In strepto-
zotocin-treated mice, a widely used rodent model of some 
aspects of DNP, progressive loss of motor fibers becomes 
apparent with age, with loss of distal axons occurring prior 
to proximal axons and motoneuron cell bodies [39]. In the 
same model, reduced insulin-like growth factor 1 (IGF1) 
expression [53] and elevated renal insulin-like growth fac-
tor-binding protein 5 (IGFBP5) levels were found [35], but 
the relevance of these findings for DNP remained unclear. 
IGF1 and IGF2 are pluripotent growth and survival factors 
for a variety of cell types [42]. They support the survival 
of motoneurons in vitro and in vivo [20, 33]. Igf1 knock-
out mice show multiple defects including reduced myelina-
tion and loss of striatal neurons [3]. IGF1 is expressed in 
Schwann cells of peripheral nerves in developing and post-
natal rodents [10]. It acts on Schwann cells, in particular 
by stimulating myelination [11, 46], and possibly also on 
myelinated axons [31]. In transgenic mice overexpressing 
IGF1, enhanced myelin production was among the most 
prominent effects [9, 55].
The biological functions of IGF1 and IGF2 are modulated 
by at least 6 binding proteins (IGFBPs) [14, 27, 54]. Some of 
these binding proteins are produced in the liver and function 
as carriers for IGFs in the circulation [13]. Other IGFBPs 
are expressed in specific tissues and are thought to increase 
local concentrations of IGFs by trapping circulating IGF1 
and/or IGF2, as well as to compete with cellular receptors 
for IGF binding [1, 24]. Thus, they are potential regulators 
of the local availability and biological functions of IGFs. 
IGFBP5, a 29-kDa glycosylated protein [15], is a high affin-
ity binding protein for IGF1, which, at least in vitro, inhib-
its receptor binding of IGFs resulting in reduced receptor 
autophosphorylation [26]. IGFBP5 is widely expressed 
in the body including in the kidney [35, 38] and the nerv-
ous system [4, 44]. In postnatal peripheral nerves, IGFBP5 
immunoreactivity is detectable in close association with or 
within myelinated axons, suggesting that it is anterogradely 
transported and released from axons [12, 46]. IGFBP5 binds 
with high affinity to extracellular matrix (ECM) [14, 25]. 
Thus, IGFBP5 may be involved in regulating local functions 
of IGF1 and IGF2 at the interface between motoneurons 
and Schwann cells. To study the role of the IGF1/IGFBP5/
IGF1R system for axon maintenance, we investigated altera-
tions of expression of IGFs and IGFBPs in peripheral nerves 
of patients with DNP and compared them with other neu-
ropathies and healthy controls. We found that IGFBP5 levels 
are increased in sural nerve biopsies of patients with senso-
rimotor DNP. To determine the pathogenic role of elevated 
IGFBP5, we established transgenic mouse lines in which 
IGFBP5 is overexpressed specifically in neurons under the 
control of the neurofilament-light chain (NF-L) promoter 
and found a progressive neuropathy in these mutants that 
affected both sensory and motor nerve fibers. We also tested 
whether reduced availability of IGF1 may be responsible 
for the degeneration of motoneurons by establishing mice 
in which the IGF1R is inactivated in motoneurons. In these 
mice, we observed a progressive degeneration of motor 
axons and cell bodies. These results indicate that elevated 
expression of IGFBP5 along with inhibition of IGF1 sign-
aling in motoneurons leads to degeneration of their axons 
and cell bodies and suggest a causative link. Thus, increased 
expression of IGFBP5 may play a role in the pathogenesis of 
sensory defects and motor axonopathy associated with DNP.
Materials and methods
Animals
The generation of the Igfbp5 tg+ (Bp5 tg+) and cIgf1r ko 
mice is described in the supplementary methods section. 
Analyses with these mouse lines were performed between 
the 4th and the 12th generation of backcrossing of these 
mice onto a C57Bl/6J background. Animals were kept in 
a temperature-controlled environment with a 12-h-light/12-
h-dark cycle. For details of behavioral analyses see supple-
mentary methods section.
Sural nerve biopsies
Diagnostic nerve biopsies were obtained from the Depart-
ment of Neurology, Würzburg. Diabetic neuropathy (DNP, 
n = 6, one type I, five type II) was diagnosed according 
to established criteria [34] after excluding other causes of 
polyneuropathy [49]. Chronic inflammatory demyelinating 
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polyradiculoneuropathy (CIDP, n = 9) was diagnosed 
according to INCAT criteria [19]. DNP in combination 
with CIDP [23] was diagnosed in four patients with type 
II diabetes showing marked motor impairment and promi-
nent demyelination in the sural nerve with reduced nerve 
conduction velocities thus fulfilling the INCAT criteria [19] 
for CIDP. All 19 patients had motor nerve abnormalities 
when tested by standard nerve conduction testing and elec-
tromyography [21, 28]. Samples from three patients with 
non-diabetic neuropathy were included as disease controls: 
mild axonal neuropathy with motor neuron disease (n = 2) 
and vitamin B12 deficiency (n = 1). Non-diseased control 
tissues (n = 5) were taken from biopsy and autopsy mate-
rial that was checked for absence of pathology. For details 
see electronic supplementary Table A2.
Immunohistochemistry
Human nerves were fixed for 24 h in 4 % PFA at 4 °C. 
10 μm frozen transverse nerve sections were prepared. 
Mice were perfused with 4 % PFA and sciatic nerves were 
dissected. Sections were incubated overnight with pri-
mary antibodies: neurofilament (1:500, Covance), IGFBP5 
(1:200, Abcam), laminin B1 (1:500; Millipore). Sections 
were then washed and incubated with secondary antibodies 
conjugated to FITC (1:40, Dako), Alexa Fluor 633 (1:500, 
Invitrogen) or Cy3 (1:600, Jackson ImmunoResearch Lab-
oratories, Inc) for 1 h, mounted and investigated with the 
Olympus FluoView™ FV1000 microscope.
Motoneuron culture
Murine embryonic spinal motoneurons were cultured as 
described [52]. BDNF, human IGF1 (PeProTech) and mouse 
IGFBP5 (BP5DU020, GroPep) were used at the concentra-
tions indicated. Cells were initially counted 4 h after plat-
ing to obtain the reference value for 100 % survival. After 
7 DIV, surviving motoneuron cells were counted again. For 
IGF1 stimulation experiments, motoneurons were cultured 
for 5 days with 5 ng/ml BDNF in full medium, and then 
starved in the same medium without horse serum and BDNF 
for 12 h. Cells were then stimulated with IGF1. Neurons 
were fixed with 4 % PFA and stained with anti-Tau (1:1000, 
Sigma) and anti-IGFBP5 (1:500, Neuromics) antibodies. 
Cellular morphology was visualized with fluorescence-
coupled secondary antibodies (Jackson ImmunoResearch) 
using a Leica SP2 confocal microscope. Measurements 
were done with the Leica AS Lite software (Leica).
Dorsal root ganglionic (DRG) sensory neuronal culture
Murine embryonic DRGs were isolated and cultured 
as described previously [22]. For IGF1 stimulation 
experiments, DRG neurons were cultured with neuroba-
sal medium (NB) in the presence of 2 % horse serum, 2 % 
B27 and 10 ng/ml NGF (PeProTech) for 20 h. Cells were 
starved for 4 h in NB after three washing steps with NB 
to minimize NGF levels. DRGs were then stimulated with 
either 10 ng/ml NGF, 20 ng/ml human IGF1 (PeProTech) 
or 20 ng/ml human IGF1 and 200 ng/ml mouse IGFBP5 
(BP5DU020, GroPep), respectively. Subsequently, cells 
were washed with phosphate buffer saline and lysed for 
10 min at 4 °C with lysis buffer comprising 50 mM Tris–
HCl (pH 7.4), 150 mM NaCl, 1 % Triton-X-100, Protease- 
and Phosphatase inhibitors (Thermo Scientific). Equal vol-
umes of DRG cell lysates were loaded onto 12 % SDS gels 
and immunoblotted for IGF1R, pIGF1R, AKT, pAKT and 
calnexin.
Western blot analysis
Protein was isolated from nerve biopsies homogenized 
in lysis buffer (150 mM NaCl, 1 % Triton, 2 mM EDTA, 
50 mM Tris, pH 7.4). 30 µg protein extract was electro-
phoresed on a 12 % SDS-PAGE gel and blotted for 40 min 
to PVDF membrane. The membranes were probed with 
rabbit anti-IGFBP5 (H-100, 1:5000, Santa Cruz Biotech-
nology) for human samples and goat anti-IGFBP5 antibody 
(GT15183, 1:5000, Neuromics) for murine samples in 
5 % skim milk, and rabbit anti-phosho-IGF1 receptor beta 
(3918, 1:2000) in 5 % BSA, anti-IGF1 receptor beta (3027, 
1:2000) in 5 % milk, for immunoprecipitation 1:1000 in 
combination with protein A agarose beads (11719386001, 
Roche), anti-phospho-Akt (9271, 1:2000 in 5 % BSA) and 
anti-Akt (9272, 1:2000 in 5 % milk, all from Cell Signal-
ing Technology) for mouse extracts, in blocking buffer for 
1 h. The appropriate HRP-conjugated secondary antibody 
(Jackson ImmunoResearch Laboratories, Inc) was used and 
visualized using enhanced chemiluminescence (GE Health-
care, Lifesciences). The blots were reprobed with mouse 
anti-actin antibody (Clone C4, 1:7000, Millipore). Film 
images were scanned and the intensity of IGFBP5 was 
standardized to mouse anti-actin. A minimum of n = 3 per 
group were tested in 3 independent experiments.
Quantitative morphometry on cross sections of the 
phrenic and sciatic nerve
The morphological analysis of phrenic and sciatic nerve 
axons was carried out in Igfbp5 transgenic mice derived 
from mouse line 8 at 3 weeks (wt: n = 4; Bp5 tg+: n = 6) 
and 5 to 6 months (wt: n = 5; Bp5 tg+: n = 3) of age and 
in 5- to 6-month-old transgenic mice derived from mouse 
line 9 (n = 3). In addition, the phrenic and sciatic nerve 
axons were analyzed in 4 cIgf1r ko and 4 wild-type mice 
at 6 months of age. Mice were transcardially perfused with 
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0.1 M phosphate buffer followed by a mixture of 4 % para-
formaldehyde and 2 % glutaraldehyde in 0.1 M cacodylate 
buffer. The proximal part of the phrenic nerves was then 
dissected and postfixed in the same fixative overnight. After 
osmification and dehydration, all samples were embedded 
in Spurr`s medium. Semithin (1 µm) cross sections for light 
microscopic examination were cut with a diamond knife on 
an ultramicrotome. Sections were stained with azur–meth-
ylene blue for histomorphological analysis and subsequent 
morphometric evaluation. The nerve sections of Igfbp5 
tg+ mice were analyzed under a light microscope (Leica 
GmbH, Bensheim, Germany) and morphometric evalua-
tion of phrenic and sciatic nerves was performed using the 
Quantimed 500 morphometric system (Leica GmbH, Ben-
sheim, Germany). The number of intact myelinated fibers 
in motoneuron-specific Igf1r mutant mice was determined 
from photographs taken from nerve cross sections under 
an Leica (Nussloch, Germany) light microscope equipped 
with a digital camera (ActionCam; Agfa, Mortsel, Bel-
gium). To estimate the total number and relative axon size 
distributions in sciatic nerves, 4 cIgf1r ko and 4 wild-type 
mice were prepared as described above. A segment of the 
main sciatic nerve trunk was taken from a standard site. 
Cross sections were photographed using a Zeiss Axiophot 
microscope in conjugation with a digital Spot Insight Cam-
era with corresponding Spot Software (Visitron Systems 
GmbH, Puchheim, Germany). The stereological analysis of 
myelinated axons was carried out on a Vario Vision Docu 
software analysis system (Vario Vision Docu; Soft Imag-
ing System, Münster, Germany). To obtain unbiased num-
ber and size estimates from a sample of axons in a nerve 
cross section, we followed the concept of systematic ran-
dom sampling using a systematically positioned unbiased 
counting frame [18]. The entire nerve cross sections were 
photographed at low magnification (200×) and the entire 
nerve cross section areas were determined. Approximately 
10 high magnification photomicrographs (1000×) were 
taken from each nerve cross section. The counting frame 
(2500 µm2) was systematically placed into the lower right 
corner of each photomicrograph covering at least one-half 
of the nerve cross section. Axons in the frame or at the 
(dashed) inclusion lines were counted provided that they 
do not in any way touch the (solid) exclusion lines or their 
infinite extensions. Approximately 300–600 axons were 
counted in 6–8 micrographs per nerve cross section. Esti-
mates of the total number of axons were calculated as: total 
number of axons counted divided by the product of num-
ber and area of the counting frames multiplied by the area 
of the nerve cross section. Absolute and relative size dis-
tributions of myelinated axons were measured on the same 
photomicrograph so that number and size estimations were 
combined into one complete procedure. The cross-sectional 
area of the axons was determined by tracing them with a 
cursor on a digitizing tablet of the Vario Vision Docu analy-
sis system. The M-ratio was calculated by the division of 
myelin thickness by axon diameter. At least 150 M-ratios 
and circumferences per nerve were measured in at least 3 
individuals per group.
Intraepidermal nerve fiber density (IENFD)
Foot pads were collected from the plantar surface of the 
hind paw, immersion fixed with 4 % paraformaldehyde 
for 2 h, cryoprotected overnight in 30 % sucrose, cryoem-
bedded in mounting media (OCT), and 12 μm cryostat 
sections were prepared. Sections were labeled using rab-
bit polyclonal antibodies against PGP9.5 (1:800, Ultra 
clone limited, RA95101) and donkey anti-rabbit (H+L) 
IgG Cy3-conjugated secondary antibodies (1:700, Jackson 
Immunoresearch). Images were acquired using a Leica SP2 
confocal microscope system (Leica Microsystems) and a 
40× oil immersion objective. Eight confocal images were 
captured at 1 µm intervals and an average projection image 
was produced by ImageJ (MacBiophotonics). Images were 
analyzed using the Leica LAS AF Lite software. Individual 
intraepidermal nerve fibers which passed through the base-
ment membrane were scored from individual sections of 
independent animals. In total, 16 sections from footpads 
from 4 wild-type and 21 sections from footpads from 4 
Igfbp5 transgenic mice were scored. IENFD data are pre-
sented and statistically analyzed as the mean number of 
nerve fibers per mm2 of epidermis. For visual presentation, 
linear brightness and contrast correction was performed 
consistently in the corresponding images without changing 
image information.
Electrophysiology
Analyses of nerve conduction studies were initially per-
formed with a Toennies electromyograph (Toennies, Wür-
zburg) and later with a digital Neurosoft-Evidence 3102 
electromyograph (Schreiber & Tholen Medizintechnik). 
Motor and compound sensory–motor nerve conduction 
was investigated in the sciatic nerve in mutant and control 
mice using techniques described previously for numerous 
mutant mouse lines [6, 29, 57]. For details see supplemen-
tary methods section.
Statistical analysis
All data are expressed as mean ± SD (*P < 0.05, 
**P < 0.01, ***P < 0.001). For statistical analysis, 3 inde-
pendent experiments were conducted. After testing for 
normal distribution, the data were subjected to a statistical 
analysis with two-tailed Student’s t test when comparing 
two groups and one-way ANOVA with the Tukey post hoc 
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test for comparison of more than 2 groups. The frequency 
distribution of axon circumferences was analyzed by two-
way ANOVA with the Bonferroni post hoc test. Statisti-
cal analysis was performed with Graph Pad Prism4 Soft-
ware (San Diego, USA). Final figures were arranged using 
ImageJ, Adobe Photoshop and Adobe Illustrator CS6.
Results
IGFBP5 protein levels are elevated in nerve biopsies 
in DNP
Previous studies have shown that IGF1 levels are down-
regulated in peripheral nerves in diabetic [53] and non-
diabetic [16] types of neuropathy. We therefore investigated 
the expression of IGF family members, their receptors and 
IGFBPs by microarray expression analysis of sural nerve 
biopsies from patients with DNP and age-matched control 
individuals (electronic supplementary Table A1). Microar-
ray expression analysis revealed a decrease of IGF1 mRNA 
levels and more than sevenfold up-regulation of IGFBP5 
expression in DNP. These findings were corroborated by 
Western blotting using protein extracts from sural nerve 
biopsies (Fig. 1a). IGFBP5 protein levels were more than 
5-fold up-regulated in 6 patients with DNP (P < 0.01, one-
way ANOVA) (see electronic supplementary Table 2 for 
clinical characteristics of these patients) and in 3 patients 
with combined diabetic neuropathy and chronic inflamma-
tory demyelinating polyradiculoneuropathy (DNP+CIDP; 
P < 0.001, one-way ANOVA) as compared to CIDP indi-
viduals (Fig. 1b, c) and 50-fold in comparison to healthy 
Fig. 1  IGFBP5 protein levels 
are significantly up-regulated 
in biopsies of DNP patients. 
a Western blots of IGFBP5 
protein levels in human sural 
nerve from control (C) individu-
als (3 samples shown from a 
total of 5 analyzed), patients (P) 
with DNP, CIDP, DNP+CIDP 
(3 samples shown from 4 in 
total) and other neuropathies 
(ONP; axonal neuropathy in 
motor neuron disease (O1, O3), 
vitamin B12 deficiency (O2). 
b IGFBP5 protein levels were 
specifically up-regulated in 
patients with DNP. Biopsies of 
patients with DNP showed on 
average a 5-fold up-regulation 
compared to CIDP individuals 
and 50-fold in comparison to 
healthy controls. Up-regulation 
in DNP patients with additional 
CIDP was not significantly 
higher than in patients with 
DNP alone. Other neuropathies 
(ONP) and patients with CIDP 
showed no significant change 
in comparison to controls. All 
values were normalized to 
CIDP biopsies. QL: quantitative 
labeling. c IGFBP5 (green) and 
neurofilament (red) distribution 
in human sural nerves from a 
control individual and a patient 
with DNP. Note that IGFBP5 
levels were increased in axons 
and in the extracellular matrix 
(ECM) (arrows) in DNP. Scale 
bar 5 μm
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controls (P < 0.001, one-way ANOVA). Increased IGFBP5 
protein levels were only observed in 2 out of 9 CIDP 
patients, and did not reach statistical significance when 
compared with controls (P > 0.05, one-way ANOVA). This 
suggests an association of IGFBP5 overexpression with 
DNP rather than with the superimposed CIDP in this mixed 
group. IGFBP5 expression was also low in the 3 patients 
with non-diabetic neuropathy (P > 0.05, one-way ANOVA) 
(Fig. 1a, b). This indicates that levels of IGFBP5 are specif-
ically up-regulated in patients with DNP. Enhanced levels 
of IGFBP5 could also be detected by immunohistochem-
istry in peripheral nerve sections (Fig. 1c), particularly in 
axons, as revealed by co-localization with neurofilament 
H immunoreactivity. IGFBP5 immunoreactivity was also 
observed in the extracellular matrix surrounding the axons 
(arrows in Fig. 1c).
IGFBP5 inhibits motoneuron survival and axon growth
Based on the significant up-regulation of IGFBP5 expres-
sion in nerves of diabetic patients, we investigated whether 
IGFBP5 interferes with the effects of IGF1 on cultured spi-
nal motoneurons, grown for 7 days with IGF1 or BDNF 
(5 ng/ml) alone, or in combination with IGFBP5 (80 ng/
ml). IGF1 and BDNF had potent effects on motoneu-
ron survival (P < 0.001, one-way ANOVA). IGF1 main-
tained 43 % of initially plated motoneurons; BDNF main-
tained 50 % (Fig. 2a). Addition of IGFBP5 (80 ng/ml) 
reduced IGF1-mediated survival rates to 20 % (P < 0.001, 
one-way ANOVA), whereas BDNF-mediated survival 
rates remained unaffected (P > 0.05, one-way ANOVA) 
(Fig. 2a). We then tested the phosphorylation of the IGF1R 
and downstream AKT with increasing IGF1 concentra-
tions (Fig. 2b). We found maximal activation of the recep-
tor and phosphorylation of downstream AKT with 20 ng/
ml IGF1 (P < 0.001, one-way ANOVA) (Fig. 2b–d). Addi-
tion of IGFBP5 (200 ng/ml) led to significant reduction 
of IGF1R (P < 0.05, one-way ANOVA), and downstream 
AKT phosphorylation (P < 0.01, one-way ANOVA), indi-
cating that IGFBP5 is inhibitory for IGF1R activation and 
survival in cultures of isolated motoneurons (Fig. 2b–d). 
Similar observations were made with sensory neurons from 
embryonic lumbar DRGs (Fig. 2e–g). IGFBP5 reduced 
IGF-mediated activation of the IGF1R (P < 0.05, one-way 
ANOVA) and AKT (P < 0.05, one-way ANOVA). AKT 
activation by NGF was not affected.
To study this effect on motoneurons and sensory neurons 
in vivo, we generated mice with neuron-specific overexpres-
sion of IGFBP5. An 8-kb fragment including the human 
NF-L promoter, mouse Igfbp5 cDNA, the polyA signal from 
pMC-Cre and exons 2–4 of the NF-L gene was injected into 
fertilized mouse eggs (for details see electronic supplemen-
tary Fig. A1, supplementary methods section). Real-time 
RT-PCR analysis revealed that the levels of Igfbp5 mRNA in 
the spinal cord of 6 months old Igfbp5 transgenic mice (Bp5 
tg+) were up-regulated 1.8-fold compared with controls 
(P < 0.001, two-tailed Student’s t test) (Fig. 3a). Western blot 
analysis for IGFBP5 in the spinal cord, sciatic nerve and brain 
of 6-month-old Igfbp5 transgenic mice exhibited a fivefold 
IGFBP5 protein up-regulation in the sciatic nerve (P < 0.001, 
two-tailed Student’s t test) (Fig. 3b, c), indicating that the 
IGFBP5 protein is anterogradely transported in axons. Iso-
lated motoneurons from Igfbp5 transgenic embryos (E13.5) 
also showed increased IGFBP5 immunoreactivity in cell 
bodies and axons after 7 days in vitro (Fig. 3d). IGFBP5 was 
predominantly localized on the surface of these neurons. This 
correlates with previous data showing that IGFBP5 binds to 
the cell surface and the surrounding extracellular matrix [2]. 
Igfbp5 transgenic motoneurons showed a different survival 
response to IGF1 than wild-type motoneurons. While sur-
vival of Igfbp5-overexpressing motoneurons was unchanged 
in the presence of BDNF (P > 0.05, one-way ANOVA), their 
survival was significantly reduced by 37 % in the presence 
of IGF1 compared to wild-type motoneurons (P < 0.001, 
one-way ANOVA) (Fig. 3e). When we compared the dose 
response for IGF1 on motoneuron survival in Igfbp5 trans-
genic and wild-type motoneurons, a shift was observed (0.2 
ng/ml IGF1; P < 0.05; 1 ng/ml IGF1; P < 0.001; 5 ng/ml 
IGF1; P < 0.001; one-way ANOVA) (Fig. 4a), indicating that 
motoneurons overexpressing IGFBP5 need more IGF1 for 
their survival than non-transgenic motoneurons. This result 
provides further evidence that IGFBP5 inhibits IGF1 actions 
on motoneurons. We then compared the phosphorylation 
levels of IGF1R and downstream AKT in Igfbp5 transgenic 
motoneurons relative to wild-type controls. A strong reduc-
tion in IGF1R and AKT phosphorylation levels was observed 
in Igfbp5 transgenic motoneurons compared to controls 
(pIGF1R: P < 0.001; pAKT: P < 0.01, two-tailed Student’s t 
test) grown for 5 days with 5 ng/ml BDNF, then starved over-
night and pulsed for 20 min with 20 ng/ml IGF1 (Fig. 4b–d). 
Motoneurons overexpressing IGFBP5 also exhibited reduced 
axon growth (Fig. 4e, f), when cultured with IGF1 at a con-
centration of 5 ng/ml (P < 0.001, one-way ANOVA). Axon 
growth was normal when these motoneurons were cultured 
with 5 ng/ml BDNF (P > 0.05, one-way ANOVA), indicating 
that IGFBP5 not only reduces survival but also specifically 
inhibits the effects of IGF1 on axon growth.
Neuronal IGFBP5 overexpression leads to impaired 
motor function, degeneration and loss of motor axons 
and cell bodies
To test whether neuronal IGFBP5 overexpression reduces 
responsiveness to endogenous IGF1, we immunoprecipi-
tated the IGF1R from the spinal cord and sciatic nerve 
of 4-day-old Igfbp5 transgenic mice, a time period when 
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endogenous IGF1 levels are high. Analyses of spinal cord 
and sciatic nerve extracts by Western blot with a specific 
pIGF1R antibody revealed a significant 35 % reduction in 
the phosphorylation of the IGF1R (P < 0.01, two-tailed 
Student’s t test) (Fig. 5a, b). Elevated IGFBP5 immunore-
activity was observed in axons of the sciatic nerve and the 
extracellular matrix of Igfbp5 transgenic mice (see arrows 
in Fig. 5c), closely resembling the distribution of IGFBP5 
in sural nerve biopsies of patients with DNP (Fig. 1d).
Next, we investigated the morphology of peripheral 
nerves. The number of sciatic nerve axons in Igfbp5 
transgenic mice was reduced by 14 % when compared 
to wild-type animals at 6 months of age (P < 0.05, two-
tailed Student’s t test) (Figs. 5e, 6b, c [arrows indicate 
Fig. 2  IGFBP5 decreases the 
survival promoting downstream 
effect of IGF1 on isolated wild-
type motoneurons. a IGFBP5 
(BP5) reduced IGF1-mediated 
survival effects from 43 to 20 % 
on wild-type motoneurons after 
7 days in culture, while IGFBP5 
did not inhibit BDNF-mediated 
survival. b Downstream activa-
tion of IGF1 signaling pathway 
in wild-type motoneurons after 
stimulation with different IGF1 
concentrations. Wild-type moto-
neuron cell cultures were grown 
for 5 days with 5 ng/ml BDNF, 
starved overnight and pulsed 
for 20 min with indicated IGF1 
concentrations. Western blot 
analyses revealed the strongest 
phosphorylation of IGF1R (b, c) 
and AKT (b, d) with 20 ng/ml 
IGF1. e Downstream activation 
of IGF1 signaling pathway in 
wild-type DRGs after stimu-
lation with IGF1. Wild-type 
DRG cell cultures were grown 
for 20 h with 10 ng/ml NGF, 
starved for 4 h and pulsed for 
20 min with indicated factors. 
Western blot analyses revealed 
the strongest phosphorylation 
of IGF1R (e, f) and AKT (e, g) 
with 20 ng/ml IGF1
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degenerating axons], electronic supplementary Table 
A3). In parallel, a change in fiber size distribution in the 
sciatic nerve became apparent, with a significant reduc-
tion of fibers with a circumference between 20–25 µm 
in IGFBP5-overexpressing mice (P < 0.01, two-way 
ANOVA) (Fig. 5f). In addition, the M-ratio was signifi-
cantly reduced by 20 % in transgenic animals (P < 0.05, 
two-tailed Student’s t test) (Fig. 5d, g). Quantification 
of myelinated axons in the phrenic nerve of 3-week-old 
Igfbp5 transgenic mice revealed a significant axonal loss 
of 15 % (P < 0.01, two-tailed Student’s t test) (Fig. 6e; 
electronic supplementary Table A3). No further loss of 
phrenic nerve fibers was detected in 5- to 6-month-old 
Igfbp5 transgenic mice (electronic supplementary Table 
A3; Fig. 6a). These data suggest that local inhibition of 
IGF1 not only affects motor axons but also the degree 
of myelination in Schwann cells. To determine whether 
axon degeneration and axon loss reflected loss of moto-
neuron cell bodies, we also counted motoneurons in the 
facial nucleus and the lumbar spinal cord of wild-type 
and Igfbp5 transgenic mice at different stages of post-
natal development. In newborn and 3-week-old animals 
(Fig. 6f), numbers of facial motoneurons were not sig-
nificantly different between wild-type and Igfbp5 trans-
genic mice (P > 0.05, one-way ANOVA) (electronic sup-
plementary Table A3), indicating that neuronal IGFBP5 
overexpression has no effect on the generation and 
developmental cell death of motoneurons. However, by 
Fig. 3  Igfbp5 tg+ motoneurons 
show decreased survival when 
cultured with IGF1. a qRT-PCR 
revealed a 1.8-fold increase 
of the Igfbp5 mRNA level in 
the spinal cord of 6-month-old 
Igfbp5 tg+ mice (Bp5 tg+). 
Scored values were obtained by 
normalizing to β-actin mRNA 
levels. A.U. arbitrary units. b 
Igfbp5 protein elevation was 
detected in sciatic nerve, but 
not in spinal cord and brain of 
6-month-old Igfbp5 tg+ mice 
compared to controls. Actin 
was used as loading control. c 
Quantification of Igfbp5 protein 
levels. QL quantitative labeling. 
d Motoneurons stained for 
Tau (red) and Igfbp5 (green) 
7 days after plating. Igfbp5 was 
increased in the soma and neur-
ites of Igfbp5 tg+ motoneurons. 
Igfbp5 appeared associated with 
the cell membrane. Scale bar 
5 μm. e The positive effect of 
IGF1 on motoneuron survival 
is reduced by 37 % in Igfbp5 
tg+ motoneurons. Motoneuron 
survival was unchanged in the 
presence of BDNF
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5–6 months of age, a 17 % loss of facial motoneurons 
became apparent (P < 0.01, one-way ANOVA) (Fig. 6f; 
electronic supplementary Table A3). In the spinal cord, 
no significant loss of motoneurons could be observed at 
4 months of age (P > 0.05, one-way ANOVA). In con-
trast, at 5–6 months, a 20 % loss of motoneurons was 
observed (P < 0.001, one-way ANOVA) (Fig. 6g, elec-
tronic supplementary Table A3) and remaining spinal 
motoneurons exhibited signs of atrophy (Fig. 6d, indi-
cated by white arrows). At 16 months, the level of moto-
neuron loss remained at 20 %, indicating that spinal 
motoneuron loss was maximal by 5–6 months and did not 
progress thereafter (P < 0.05, one-way ANOVA) (Fig. 6g; 
electronic supplementary Table A3). Nine-month-old 
Igfbp5 transgenic mice showed a significant reduction 
of forelimb grip strength (P < 0.001, one-way ANOVA) 
(Fig. 6h). In 5- to 6-month-old Igfbp5 transgenic mice, 
nerve conduction studies of the sciatic nerve [6, 29, 
57] revealed that motor nerve conduction velocities 
(M-NCVs) were reduced by 18 % when compared to 
controls (P < 0.05; two-tailed Student’s t test) (Fig. 6i), 
which is compatible with a mild, putatively secondary 
demyelinating component of the neuropathy. Amplitudes 
of distal compound muscle action potentials (CMAPs) 
and compound sensory–motor nerve conduction veloci-
ties (cSNCVs) were not significantly altered (P > 0.05; 
two-tailed Student’s t test) (Fig. 6j, k; electronic supple-
mentary Fig. A1).
Fig. 4  Reduced phosphorylation of IGF1 receptor in Igfp5 tg+ 
motoneurons leads to reduced survival and axon outgrowth. a Dose–
response curve for IGF1-mediated motoneuron survival. Wild-type 
and Igfp5 tg+ motoneurons (7 DIV) were treated with different IGF1 
concentrations. b Reduced phosphorylation of IGF1 receptor and 
AKT in Igfbp5 tg+ motoneurons compared to wild-type motoneu-
rons. c Quantification of pIGF1R protein levels in motoneurons. d 
Quantification of pAKT protein levels in motoneurons. e Images of 
cultured wild-type motoneurons stained against Tau to identify axons. 
Scale bar 100 μm. f Igfbp5 (BP5) inhibited IGF1-induced axon out-
growth in wild-type motoneurons. Igfbp5 tg+ motoneurons showed 
shorter axons than wild-type axons when cultured with IGF1. Axon 
growth stimulated by BDNF was not affected in Igfbp5 tg+ motoneu-
rons
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Sensory defects in Igfbp5 transgenic mice
Since sensory defects are a hallmark of diabetic neuropathy, 
we studied a sensory nerve (saphenous nerve) in IGFBP5-
overexpressing mice in more detail and also tested behavioral 
parameters of sensory function. The gross overall morphology 
of the saphenous nerve appeared unaltered in 10–11 month-
old Igfbp5 transgenic mice compared with that of age-matched 
wild-type mice (electronic supplementary Fig. A2). Neverthe-
less, 10–11 month-old Igfbp5 transgenic mice demonstrated a 
higher withdrawal threshold in the von Frey hair stimulation 
test (P < 0.01, two-tailed Student’s t test) and thermal hypoal-
gesia test as illustrated by longer withdrawal latencies to a 
noxious heat stimulus in the Hargreaves test (P < 0.001, two-
tailed Student’s t test) (electronic supplementary Fig. A3). This 
indicates that sensory neurons are also affected in Igfbp5 trans-
genic mice. In addition, deficits in coordination and balance 
were revealed on an accelerating rotarod. 9-Month-old Igfbp5 
transgenic mice fell from the device in significantly less time 
than control animals (P < 0.001, one-way ANOVA) (elec-
tronic supplementary Fig. A3), whereas younger 2-month-old 
mice did not show any deficits in this test.
In the glabrous footpad skin, almost all nerve fibers in 
the epidermis are unmyelinated free nerve endings [58] and 
can be visualized using the pan-neuronal marker PGP9.5. 
The density of PGP9.5-positive fibers which passed 
through the basement membrane of the epidermis appeared 
significantly reduced in 10-month-old Igfbp5 transgenic 
mice (P < 0.01, two-tailed Student’s t test) (electronic sup-
plementary Fig. A3). In line with this observation, reduced 
substance P levels were found in the footpad of 10-month-
old Igfbp5 transgenic mice compared with control animals 
(P < 0.05, two-tailed Student’s t test) (electronic supple-
mentary Fig. A3).
Fig. 5  IGFBP5-overexpressing 
mice show decreased activa-
tion of IGF1 receptor that 
corresponds to motoneuron 
degeneration and myelination 
defects. a, b Immunoprecipita-
tion of the IGF1 receptor from 
spinal cord (left panel) and 
sciatic nerve (right panel) 
extracts of 4-day-old mice and 
subsequent analysis of phos-
phorylation showed decreased 
activation levels in Igfbp5 tg+ 
mice compared to controls. SN 
supernatant, IP immunoprecipi-
tation. c Localization of Igfbp5 
in cross sections of sciatic 
nerves. Igfbp5 was increased in 
axons and extracellular matrix 
of Igfbp5 tg+ mice. Arrows 
depict extracellular matrix 
staining. Scale bar 5 µm. d Rep-
resentative photomicrograph of 
myelinated fibers in semithin 
cross sections of the sciatic 
nerve of 6-month-old wild-type 
and Igfbp5 tg+ animals. Scale 
bar 10 µm. e 5- to 6-month-old 
Igfbp5 tg+ mice showed a 14 % 
loss of sciatic nerve fibers. f The 
frequency of fibers with a cir-
cumference between 20–25 μm 
was decreased by 4.5 % in the 
sciatic nerve of 6-month-old 
Igfbp5 tg+ mice. g The M-ratio 
was significantly reduced by 
20 % in 6-month-old Igfbp5 
tg+ mice
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Fig. 6  Nerve fiber degeneration 
and spinal motoneuron loss are 
partly reflected in electrophysi-
ological alterations in motor 
nerves of Igfbp5 transgenic 
mice. a Light micrographs of 
6-month-old wild-type, Igfbp5 
tg+ and cIgf1r ko phrenic nerve 
semithin sections stained with 
azur–methylene blue. Scale 
bar 20 µm. b, c Sciatic nerve 
cross sections of wild-type and 
Igfbp5 tg+ mice. No degenerat-
ing fibers were detectable in 
control tissue and small fibers 
appeared normal in Igfbp5 tg+ 
mice. Larger fibers of 6-month-
old wild-type and Igfbp5 tg+ 
mice (arrows) showed signs of 
degeneration. Scale bar 10 μm. 
d Nissl-stained paraffin sec-
tions of the lumbar spinal cord 
showed degenerating moto-
neurons in Igfbp5 tg+ mice 
compared to wild-type animals. 
Scale bar 50 μm. e 3-week-old 
Igfbp5 tg+ mice showed a 15 % 
loss of phrenic nerve axons. f, 
g In 5- to 6-month-old Igfbp5 
tg+ mice, the number of facial 
motoneurons was reduced by 
17 %, and the number of lumbar 
spinal motoneurons by 20 %. h 
9-Month-old Igfbp5 tg+ mice 
showed reduced grip strength 
compared with wild-type ani-
mals. i Motor nerve conduction 
velocity (M-NCV) was reduced 
significantly in Igfbp5 tg+ 
mice by 18 % in sciatic nerve. j 
Distal compound muscle action 
potential (CMAP) amplitudes 
were not altered in Igfbp5 tg+ 
and control animals. k Com-
pound sensory–motor nerve 
conduction velocity (cSNCV) 
was not altered in Igfbp5 tg+ 
mice
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Conditional deletion of IGF1 receptor in neurons 
results in axonopathy and motoneuron loss similar 
to that seen with IGFBP5 overexpression
To investigate whether degeneration of motoneurons in 
Igfbp5 transgenic mice is caused primarily by the reduced 
availability of IGF1 for axons, or whether this is second-
ary to effects on Schwann cells, we analyzed mice lack-
ing the type 1 IGF receptor in neurons (cIgf1r ko). For this 
purpose, mice carrying loxP sites flanking exon III of the 
mouse Igf1r gene were generated (for details see electronic 
supplementary Fig. A4; supplementary methods section). 
Exon III encodes most of the cysteine-rich ligand-binding 
domain of the α-subunit of the receptor, and disruption 
of this exon generates an inactive receptor [30]. The Cre 
recombinase is controlled by the NF-L promoter which has 
been shown to be highly selective for neurons [41]. Neuron-
specific disruption of exon III was confirmed by RT-PCR 
(electronic supplementary Fig. A4). Immunoprecipitation 
of the IGF1R from spinal cord of 4-day-old cIgf1r ko mice 
revealed a 32 % reduction in IGF1R phosphorylation in the 
spinal cord (electronic supplementary Fig. A4). Histologi-
cal analysis of the sciatic nerve of cIgf1r ko mice revealed 
a 13 % reduction of nerve fibers at 6 months (P < 0.05; 
two-tailed Student’s t test) (Fig. 6c; electronic supplemen-
tary Fig. A4, electronic supplementary Table A4). As found 
in IGFBP5-overexpressing mice, cIgf1r ko mice showed 
a decrease of 6 % in fibers with a circumference between 
20–25 μm (P < 0.05, two-way ANOVA) (electronic sup-
plementary Fig. A4). As expected, the M-ratio was nor-
mal (P > 0.05, two-tailed Student’s t test) (electronic sup-
plementary Fig. A4), because IGF1 signaling in Schwann 
cells was unaffected by neuron-specific inactivation of the 
mouse Igf1r gene. The number of myelinated axons was 
also reduced by 11 % in the phrenic nerve of cIgf1r ko 
mice (P < 0.05, two-tailed Student’s t test) (Fig. 6a; elec-
tronic Table A4). In 9-month-old cIgf1r ko mice, a signifi-
cant reduction of motoneurons by 16 % was observed in 
the facial nuclei (P < 0.05, two-tailed Student’s t test) and 
by 21 % in the lumbar spinal cord (P < 0.01, two-tailed 
Student’s t test) compared to controls, an effect that was 
not observed in newborn mice (electronic supplementary 
Fig. A5 and Table A4). In addition, atrophic and degenerat-
ing motoneurons were frequently found in the spinal cord 
(Fig. 6d, indicated by white arrows). We then investigated 
potential electrophysiological alterations. Comparison of 
wild-type and cIgf1r ko mice revealed that distal compound 
motor action potentials (CMAPs), motor nerve conduction 
velocities (M-NCVs) and compound sensory–motor nerve 
conduction velocities (cSNCVs) were not significantly 
reduced in cIgf1r ko mice (P > 0.05, two-tailed Student’s 
t test) (electronic supplementary Fig. A5). A mild abnor-
mality, namely increased dispersion in the F-waves (late 
responses traveling to and returning from the anterior horn 
cells along the entire length of the peripheral nerve fibers), 
was observed (P < 0.05, two-tailed Student’s t test) (elec-
tronic supplementary Fig. A5). This finding may be an indi-
cator that some F-wave generating individual nerve fibers 
display minor conduction abnormalities at some level along 
their axons. These changes are compatible with, but not 
specific for, a mild axonal pathology [21, 57] and resemble 
features found in some patients with very early DNP [36, 
48].
Discussion
Here, we show that IGFBP5 is more than 7-fold up-regulated 
at the mRNA level and at least 5-fold at the protein level in 
diabetic nerves compared to nerves from CIDP individu-
als and 50-fold compared to nerves from non-diabetic con-
trol individuals suggesting a pathogenic role of IGFBP5 in 
diabetic neuropathy. IGFBP5 is mainly found in axons and 
within the extracellular matrix surrounding the axons, indi-
cating that it is produced in motoneurons, anterogradely 
transported and released into the extracellular space. Thus, it 
could interfere with the signaling of IGF1 derived both from 
the circulation and from contacting Schwann cells. Both 
Schwann cells and axons express IGF1 receptors, and altered 
IGF1 responses therefore could affect both axon and Schwann 
cell integrity. To test this hypothesis, two new mouse models 
were generated, with overexpression of IGFBP5 in motoneu-
rons, and specific ablation of the IGF1R in the same popula-
tion of cells. Our results show that elevated IGFBP5 protein 
levels and reduced IGF1 signaling in peripheral nerves are 
important factors contributing to progressive loss of motor 
fibers and subsequent loss of motoneurons, and they are also 
associated with classical signs of diabetic neuropathy such as 
altered thresholds for heat, pain and mechanosensation. Previ-
ous studies have reported reduced levels of circulating IGF1 as 
a common feature in diabetes, with the highest reductions seen 
at older ages and with longer duration of disease [47]. Simi-
larly, in the streptozotocin-induced rat model, reduced IGF1 
expression in peripheral nerves is observed at early stages of 
disease [53]. Our data indicate that additional components 
of IGF1 signaling are dysregulated in the peripheral nervous 
system. The IGF1R that mediates the trophic effects of IGF1 
on Schwann cells and neurons is up-regulated in nerve biop-
sies from patients, as is IGFBP5, an IGF1-binding protein that 
inhibits IGF1-mediated survival and axon growth in motoneu-
rons. IGF1 depletion in mice leads to a broad range of defects 
in the brain, with hypomyelination and loss of some neuronal 
populations in the CNS [3]. These mice die by about 2 months 
of age. Postnatally, they do not exhibit any significant loss of 
motoneuron cell bodies at early stages, indicating that moto-
neuron development during embryogenesis does not depend 
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on IGF1. Similarly, mice overexpressing IGFBP5 appear nor-
mal at birth and at younger ages; however, by 6 months of age, 
prominent dysmyelination occurs. Similarly, the loss of motor 
fibers and motoneuron cell bodies was not detectable until 
6 months of age, a stage that IGF1-deficient mice do not reach 
[3]. Interestingly, dysmyelination was not observed in cIgf1r 
ko mice, indicating that the observed defects in peripheral 
nerve myelination in IGFBP5-overexpressing mice are likely 
to be due to reduced IGF1 function in Schwann cells. These 
conditional IGF1R deletion mutants further revealed that axon 
maintenance is directly dependent on IGF1R activation, since 
loss of large motor fibers in the phrenic, facial, and the mixed 
sciatic nerve was observed in the cIgf1r ko mice. Sensory 
axons appeared affected too, reflected by altered responses to 
heat and mechanical stimulation in Igfbp5 transgenic animals. 
Furthermore, Igfbp5 transgenic mice show reduced latency to 
fall from an accelerating rotarod, pointing to the involvement 
of proprioceptive neurons. Together with the altered thresh-
olds for heat-sensing thermoreceptors, reduced substance 
P levels and reduced density of small fibers in the skin, this 
resembles classical signs of diabetic neuropathy, which affects 
both sensory neurons and motor neurons, the last named pre-
dominantly at later stages. Thus, the reduced availability of 
IGF1 coupled with elevated expression of IGFBP5 in diabetic 
nerves would be predicted to have a major effect on myelina-
tion and trophic support of axons.
Up-regulation of IGFBP5 has also been observed in other 
organs in diabetes. The mechanisms are not clear. It has 
been suggested that the IGFBP5 up-regulation is induced by 
elevated glucose [43] and reduced insulin signaling. It could 
reflect a condition in diabetes under which cells protect 
themselves against signals for growth and mitosis when they 
are metabolically dysregulated. IGF1 is a potent growth fac-
tor which mediates the cellular effects of growth hormone, 
but it also regulates maintenance and dynamics of axon 
growth [7, 8], and therefore the neuronal up-regulation of 
IGFBP5 which appears as a protective mechanism to prevent 
cell growth under the metabolic conditions of diabetes also 
prevents the IGF-1 signaling from Schwann cells which is 
necessary for axon stability, axon dynamics and excitability 
of sensory neurons [51]. In diabetic rats, IGFBP5 mRNA up-
regulation has been observed in the kidney [9, 35], suggest-
ing that elevated IGFBP5 expression levels could contribute 
to kidney dysfunction during the course of diabetes. Cell cul-
tures of cardiac fibroblasts react to elevated glucose with up-
regulation of IGFBP5 protein levels, which lead to increased 
c-Jun N-terminal kinase phosphorylation and induction of 
apoptosis in cardiomyocytes [43]. This mechanism could 
contribute to deterioration of heart function in diabetes. Fur-
thermore, elevated protein levels of IGFBP5 and reduced 
protein levels of IGF1 are found in young patients with type 
I diabetes showing decreased bone mass [32]. Increased 
levels of IGFBP5 correlate with defects in microvascular 
endothelial cells in retina and kidney [17], and it has been 
proposed that these defects could be mediated through 
altered response of these cells to IGF1. Our data showing 
that IGF1R activation is reduced in peripheral nerves from 
mice overexpressing IGFBP5, and that mice lacking IGF1R 
signaling in motoneurons show similar signs of motor neu-
ropathy as IGFBP5-overexpressing mice strongly sug-
gest that the up-regulation of IGFBP5 is also responsible 
for microangiopathy, heart failure, kidney failure, reduced 
bone mass and other pathological findings associated with 
diabetes.
Our data from mouse models suggest that inhibiting the 
up-regulation of IGFBP5 expression in peripheral nerves 
might prevent or slow down disease progression. Similarly, 
inhibitors of IGFBP5 that block binding to IGF1 could be 
of therapeutic benefit. As shown by X-ray crystallography 
[56], the domains of IGF1 that bind to IGFBP5 are differ-
ent from those that bind to the receptor. Thus, it should be 
feasible to discover inhibitors that prevent the interaction of 
IGF1 with IGFBP5, but not with the IGF1 receptor. Such 
molecules could not only prevent the loss of motor axons 
and motor function, but also the loss of myelinated sensory 
axons and thus would open new strategies for testing in 
prospective clinical trials for DNP.
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